YI-DGfI seminar series (seminars are open to everyone):
Roland Ullrich, Department I of Internal Medicine, University Hospital Cologne

Title: Lymphoma-associated myeloid-monocytic (LAMM) cells mediate resistance against CAR-T cell therapy in aggressive B-cell lymphoma
CAR-T cell therapy has improved the outcome of patients with relapsed or refractory (r/r) aggressive B cell lymphoma. However, around 60% of patients do not derive durable benefit from CAR-T cell therapy. To elucidate hallmarks associated with an immunosuppressive lymphoma microenvironment and CAR-T cell resistance, we applied high-dimensional analyses to pre- and post-CAR-T cell specimens. In patients with non-durable response, we identified a prognostically relevant lymphoma-associated myelo-monocytic (LAMM) gene signature.